A Dose Finding Study of IBI3016 in Mild to Moderate Hypertensive Patients

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2026
The purpose of this study is to evaluate the efficacy, safety and tolerability of IBI3016 or placebo, given subcutaneously, every 3 or 6 months, at different dose levels in patients with mild to moderate hypertension
Epistemonikos ID: 6ea35d1dc2567da5573a164f84803c4b220e5ce0
First added on: Jan 21, 2026